Amnis Corporation Receives Broad Patent Coverage for Diagnostic Cell Imaging

SEATTLE, April 20 /PRNewswire/ -- Amnis Corporation, a manufacturer of advanced cell imaging systems, announced today that it has received U.S. patent 7,522,758. The patent, entitled Blood and Cell Analysis Using an Imaging Flow Cytometer, broadly covers diagnostic uses of multispectral cell imaging in flow or on slides and expands the company's intellectual property estate to 32 issued U.S. patents plus multiple foreign counterparts.

"Amnis' ImageStream(R) platform was designed to achieve tremendous speed and high fluorescence sensitivity while providing rich diagnostic information in the form of multiple images per cell," remarked William Ortyn, Amnis' co-founder and Chief Operations Officer. "With its ability to image hundreds of thousands of cells in minutes, directly in flow, ImageStream combines the diagnostic strengths of high resolution microscopy and flow cytometry in a single platform," added Ortyn.

"Our technology is a natural fit for the minimally-invasive diagnostic analysis of cells in bodily fluids. ImageStream enables the identification and functional analysis of even extremely rare cells that are indicative of disease, such as circulating tumor cells," said David Basiji, Ph.D., Amnis' President and Chief Executive Officer. Basiji added, "We are actively collaborating with our clinical partners on the development of diagnostic applications and are pleased that we now have broad intellectual property in multiple diagnostic areas."

About Amnis: Amnis Corporation, headquartered in Seattle, WA, develops, manufactures and markets instrumentation for high speed cell imaging for research and diagnostic markets.

CONTACT: David Basiji, President and Chief Executive Officer of Amnis
Corporation, +1-206-374-7000, fax, +1-206-576-6895, marketing@amnis.com

Web site: http://www.amnis.com/